Recent developments in CCR2 antagonists

DOI: 10.1517/13543770902755129
Expert Opinion on Therapeutic Patents, 2009, 19, 295-303.

#	Paper	IF	Citations
149	The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. **2010**, 224, 93-100		288
148	gamma-Lactams as glycinamide replacements in cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 2425-30	2.9	20
147	Identification of a sulfonamide series of CCR2 antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 3961-4	2.9	15
146	Advances in understanding the pulmonary infiltration in acute promyelocytic leukaemia. **2010**, 151, 209-20		36
145	Pharmacological inhibition of C-C chemokine receptor 2 decreases macrophage infiltration in the aortic root of the human C-C chemokine receptor 2/apolipoprotein E-/- mouse: magnetic resonance imaging assessment. **2010**, 30, 253-9		36
144	Gene Expression Profiles from Peripheral Blood Mononuclear Cells Are Sensitive to Short Processing Delays. **2010**, 8, 153-162		31
143	Spiroindenes and spiroindanes as antagonists of CC chemokine receptor 2: WO 2009023754. *Expert Opinion on Therapeutic Patents*, **2010**, 20, 283-9	6.8	3
142	Tumor infiltrating regulatory T cells: tractable targets for immunotherapy. **2010**, 29, 461-84		5
141	Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. **2010**, 95, 31-53		66
140	CCR2 antagonists. **2010**, 10, 1278-98		83
139	Therapeutic antibodies directed at G protein-coupled receptors. **2010**, 2, 594-606		121
138	ZC3H12A (MCPIP1): molecular characteristics and clinical implications. **2010**, 411, 1862-8		14
137	Discovery of a Potent and Orally Bioavailable CCR2 and CCR5 Dual Antagonist. **2010**, 1, 14-18		32
136	Tools for analyzing cell shape changes during chemotaxis. **2010**, 2, 561-7		17
135	Macrophages recruited via CCR2 produce insulin-like growth factor-1 to repair acute skeletal muscle injury. **2011**, 25, 358-69		188
134	Novel C-C chemokine receptor 2 antagonists in metabolic disease: a review of recent developments. **2011**, 20, 745-56		46
133	Discovery of INCB3284, a Potent, Selective, and Orally Bioavailable hCCR2 Antagonist. **2011**, 2, 450-4		33

132	An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes. **2011**, 80, 68-78		91
131	Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 1442-6	2.9	28
130	The crucial role of dendritic cells in rhinitis. **2011**, 11, 12-7		4
129	Cellular and cytokine-based inflammatory processes as novel therapeutic targets for the prevention and treatment of atherosclerosis. **2011**, 131, 255-68		58
128	Overcoming hERG activity in the discovery of a series of 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 5577-82	2.9	19
127	Design, synthesis and SAR of indazole and benzoisoxazole containing 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 6042-8	2.9	12
126	The discovery of novel cyclohexylamide CCR2 antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 7496-501	2.9	9
125	CCR2 receptor antagonists: optimization of biaryl sulfonamides to increase activity in whole blood. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 7291-4	2.9	4
124	High-content analysis of CCR2 antagonists on human primary monocytes. **2011**, 16, 683-93		6
123	Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist. **2011**, 2, 913-8		33
122	Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function. **2011**, 54, 1667-81		18
121	Treatment of allergic asthma: modulation of Th2 cells and their responses. **2011**, 12, 114		133
120	Design and synthesis of novel CCR2 antagonists: investigation of non-aryl/heteroaryl binding motifs. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 1827-31	2.9	6
119	Virtual screening against obesity. **2011**, 18, 2158-73		3
118	CC and CXC chemokines are pivotal mediators of cerebral injury in ischaemic stroke. **2011**, 105, 409-20		98
117	IL-2-controlled expression of multiple T cell trafficking genes and Th2 cytokines in the regulatory T cell-deficient scurfy mice: implication to multiorgan inflammation and control of skin and lung inflammation. **2011**, 186, 1268-78		38
116	Acute skeletal muscle injury: CCL2 expression by both monocytes and injured muscle is required for repair. **2011**, 25, 3344-55		149
115	Emerging anti-inflammatory strategies for COPD. **2012**, 40, 724-41		68

114	The association of monocyte chemotactic protein-1 and CC chemokine receptor 2 gene variants with chronic obstructive pulmonary disease. **2012**, 31, 1058-63		12
113	CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms. **2012**, 287, 36593-608		135
112	Suppression of vaccine immunity by inflammatory monocytes. **2012**, 189, 5612-21		28
111	Alveolar macrophages in diabetes: friends or foes?. **2012**, 91, 871-6		13
110	A novel C-C chemokine receptor 2 antagonist prevents progression of albuminuria and atherosclerosis in mouse models. **2012**, 35, 2069-74		30
109	Investigation of sanguinarine and chelerythrine effects on LPS-induced inflammatory gene expression in THP-1 cell line. **2012**, 19, 890-5		32
108	In vivo activity of an azole series of CCR2 antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 7252-5	2.9	3
107	Benzimidazoles as benzamide replacements within cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 6181-4	2.9	5
106	Stereocalpin A inhibits the expression of adhesion molecules in activated vascular smooth muscle cells. **2012**, 12, 315-25		15
105	Relationships between serum MCP-1 and subclinical kidney disease: African American-Diabetes Heart Study. **2012**, 13, 148		14
104	IL-33 is secreted by psoriatic keratinocytes and induces pro-inflammatory cytokines via keratinocyte and mast cell activation. **2012**, 21, 892-4		74
103	Role of CCR2 in immunobiology and neurobiology. **2012**, 3, 16-29		20
102	Emerging drugs for chronic obstructive pulmonary disease. **2012**, 17, 61-82		20
101	Binding site characterization of G protein-coupled receptor by alanine-scanning mutagenesis using molecular dynamics and binding free energy approach: application to C-C chemokine receptor-2 (CCR2). **2012**, 16, 401-13		7
100	Chemokines in CNS injury and repair. **2012**, 349, 229-48		110
99	Synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamide-derived antagonists of CC chemokine receptor 2 (CCR2). *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 1384-7	2.9	3
98	Discovery of an orally-bioavailable CC Chemokine Receptor 2 antagonist derived from an acyclic diaminoalcohol backbone. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 3311-6	2.9	8
97	The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 3895-9	2.9	16

96	Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases. **2013**, 36, 1039-50		117
95	Chemokines. *Methods in Molecular Biology*, **2013**,	1.4	4
94	Novel 2-aminooctahydrocyclopentalene-3a-carboxamides as potent CCR2 antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 351-4	2.9	8
93	27-Hydroxycholesterol induces recruitment of monocytic cells by enhancing CCL2 production. **2013**, 442, 159-64		23
92	Proteinase-activated receptors (PARs) - focus on receptor-receptor-interactions and their physiological and pathophysiological impact. **2013**, 11, 86		123
91	Antagonism of human CC-chemokine receptor 4 can be achieved through three distinct binding sites on the receptor. **2013**, 1, e00019		13
90	A novel series of N-(azetidin-3-yl)-2-(heteroarylamino)acetamide CCR2 antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 1063-9	2.9	19
89	Full-length membrane-bound tumor necrosis factor-□acts through tumor necrosis factor receptor 2 to modify phenotype of sensory neurons. **2013**, 154, 1778-1782		7
88	Progress in the discovery of CC chemokine receptor 2 antagonists, 2009 - 2012. *Expert Opinion on Therapeutic Patents*, **2013**, 23, 549-68	6.8	25
87	Targeting CCR2 Receptor To Treat Inflammation Diseases and Disorders. **2013**, 4, 371-2		
86	B-cell-activating factor is a regulator of adipokines and a possible mediator between adipocytes and macrophages. **2013**, 45, e4		13
85	ATF3 Protects against LPS-Induced Inflammation in Mice via Inhibiting HMGB1 Expression. **2013**, 2013, 716481		25
84	Streptococcal-vimentin cross-reactive antibodies induce microvascular cardiac endothelial proinflammatory phenotype in rheumatic heart disease. **2013**, 173, 419-29		18
83	IB□s a transcriptional key regulator of CCL2/MCP-1. **2013**, 190, 4812-20		61
82	CC chemokine receptors and chronic inflammation--therapeutic opportunities and pharmacological challenges. **2013**, 65, 47-89		171
81	Mechanisms of HIV entry into the CNS: increased sensitivity of HIV infected CD14+CD16+ monocytes to CCL2 and key roles of CCR2, JAM-A, and ALCAM in diapedesis. *PLoS ONE*, **2013**, 8, e69270	3.7	102
80	Gene expression pattern after insertion of dexamethasone-eluting electrode into the guinea pig cochlea. *PLoS ONE*, **2014**, 9, e110238	3.7	18
79	Selective and Dual Targeting of CCR2 and CCR5 Receptors: A Current Overview. **2014**, 187-241		8

78	Positive correlation of STAT1 and miR-146a with anemia in patients with systemic lupus erythematosus. **2014**, 34, 171-80		18
77	Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset. **2014**, 16, R23		18
76	The discovery and SAR of cyclopenta[b]furans as inhibitors of CCR2. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 2137-40	2.9	4
75	Alkylsulfone-containing trisubstituted cyclohexanes as potent and bioavailable chemokine receptor 2 (CCR2) antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 1843-5	2.9	3
74	Design and synthesis of novel small molecule CCR2 antagonists: evaluation of 4-aminopiperidine derivatives. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 5377-80	2.9	5
73	ICAM-1 as a molecular target for triple negative breast cancer. **2014**, 111, 14710-5		107
72	Korean red ginseng extract alleviates atherosclerotic lesions in apolipoprotein E knockout mice. **2014**, 23, 1267-1272		3
71	Galectin-8 elicits pro-inflammatory activities in the endothelium. **2014**, 24, 966-73		31
70	The role of host genetic factors in respiratory tract infectious diseases: systematic review, meta-analyses and field synopsis. *Scientific Reports*, **2015**, 5, 16119	4.9	47
69	Thermodynamic Insights and Conceptual Design of Skin-Sensitive Chitosan Coated Ceramide/PLGA Nanodrug for Regeneration of Stratum Corneum on Atopic Dermatitis. *Scientific Reports*, **2015**, 5, 18089	4.9	23
68	Klotho gene deficiency causes salt-sensitive hypertension via monocyte chemotactic protein-1/CC chemokine receptor 2-mediated inflammation. **2015**, 26, 121-32		74
67	HPLC Determination of Enantiomeric Purity of PF-04136309 Based on a Chiral Stationary Phase. **2015**, 78, 579-583		3
66	Synthesis and biological evaluation of spirocyclic antagonists of CCR2 (chemokine CC receptor subtype 2). *Bioorganic and Medicinal Chemistry*, **2015**, 23, 4034-49	3.4	10
65	Small molecule and peptide therapies for chronic heart failure: a patent review (2011 - 2014). *Expert Opinion on Therapeutic Patents*, **2015**, 25, 1175-90	6.8	4
64	The duality of chemokines in heart failure. **2015**, 11, 523-36		1
63	Chemokines. **2015**,		4
62	Systemic delivery of proresolving lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice. **2015**, 29, 2504-13		68
61	Discovery of a Potent and Orally Bioavailable Dual Antagonist of CC Chemokine Receptors 2 and 5. **2015**, 6, 439-44		12

60	Oxidative DNA damage caused by inflammation may link to stress-induced non-targeted effects. **2015**, 356, 72-81		44
59	Targeting the CCL2-CCR2 signaling axis in cancer metastasis. **2016**, 7, 28697-710		268
58	Myeloid cell populations and fibrogenic parameters in bleomycin- and HOCl-induced fibrosis. **2016**, 25, 887-894		9
57	Purinergic Signaling During Immune Cell Trafficking. **2016**, 37, 399-411		41
56	Novel Piperazino-Enaminones Suppress Pro-Inflammatory Cytokines and Inhibit Chemokine Receptor CCR2. **2016**, 39, 2053-2061		8
55	Stereoselective Bulk Synthesis of CCR2 Antagonist BMS-741672: Assembly of an All-cis (S,R,R)-1,2,4-Triaminocyclohexane (TACH) Core via Sequential Heterogeneous Asymmetric Hydrogenations. *Organic Process Research and Development*, **2016**, 20, 1949-1966	3.9	13
54	CC chemokine ligand 2 and CXC chemokine ligand 8 as neutrophil chemoattractant factors in canine idiopathic polyarthritis. **2016**, 182, 52-58		4
53	Exenatide and metformin express their anti-inflammatory effects on human monocytes/macrophages by the attenuation of MAPKs and NFB signaling. **2016**, 389, 1103-15		24
52	High performance liquid chromatographic determination of YJC-10592, a new chemokine receptor 2 (CCR-2) antagonist, in biological samples. **2016**, 46, 495-504		4
51	Impaired phagocytosis of apoptotic cell material in serologically active clinically quiescent patients with systemic lupus erythematosis. **2016**, 19, 1310-1316		4
50	Pharmacokinetics of YJC-10592, a novel chemokine receptor 2 (CCR-2) antagonist, in rats. **2016**, 39, 833-42		4
49	Silencing CCR2 in Macrophages Alleviates Adipose Tissue Inflammation and the Associated Metabolic Syndrome in Dietary Obese Mice. *Molecular Therapy - Nucleic Acids*, **2016**, 5, e280	10.7	29
48	Discovery and synthesis of cyclohexenyl derivatives as modulators of CC chemokine receptor 2 activity. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 662-666	2.9	2
47	The respiratory DC/macrophage network at steady-state and upon influenza infection in the swine biomedical model. *Mucosal Immunology*, **2016**, 9, 835-49	9.2	45
46	Increased MCP-1 gene expression in monocytes of severe OSA patients and under intermittent hypoxia. *Sleep and Breathing*, **2016**, 20, 425-33	3.1	18
45	Fluoride-Induced Oxidative and Inflammatory Stress in Osteosarcoma Cells: Does It Affect Bone Development Pathway?. *Biological Trace Element Research*, **2017**, 175, 103-111	4.5	18
44	Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model. *Molecular Cancer Therapeutics*, **2017**, 16, 312-322	6.1	59
43	Current and novel anti-inflammatory drug targets for inhibition of cytokines and leucocyte recruitment in rheumatic diseases. *Journal of Pharmacy and Pharmacology*, **2018**, 70, 18-26	4.8	9

42	Ethanol-induced damage to the developing spinal cord: The involvement of CCR2 signaling. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2017**, 1863, 2746-2761	6.9	9
41	Monocyte chemoattractant protein-1 polymorphism interaction with spirulina immunomodulatory effects in healthy Korean elderly: A 16 week, double-blind randomized clinical trial. *Nutrition Research and Practice*, **2017**, 11, 290-299	2.1	3
40	Transcription analysis of the responses of porcine heart to Erysipelothrix rhusiopathiae. *PLoS ONE*, **2017**, 12, e0185548	3.7	3
39	In vivo immune signatures of healthy human pregnancy: Inherently inflammatory or anti-inflammatory?. *PLoS ONE*, **2017**, 12, e0177813	3.7	35
38	Bindarit Attenuates Pain and Cancer-Related Inflammation by Influencing Myeloid Cells in a Model of Bone Cancer. *Archivum Immunologiae Et Therapiae Experimentalis*, **2018**, 66, 221-229	4	6
37	Revisiting the prognostic value of monocyte chemotactic protein 1 and interleukin-6 in the sepsis-3 era. *Journal of Critical Care*, **2018**, 43, 21-28	4	15
36	Microglia prevent peripheral immune cell invasion and promote an anti-inflammatory environment in the brain of APP-PS1 transgenic mice. *Journal of Neuroinflammation*, **2018**, 15, 274	10.1	49
35	Anti-inflammatory effect on genes expression after four days of Qigong training in peripheral mononuclear blood cells in healthy women. *Annals of Agricultural and Environmental Medicine*, **2018**, 25, 329-333	1.4	7
34	Design, synthesis and biological evaluation of piperazino-enaminones as novel suppressants of pro-Inflammatory cytokines. *Bioorganic and Medicinal Chemistry*, **2018**, 26, 3890-3898	3.4	9
33	-Butyrylated hyaluronic acid ameliorates gout and hyperuricemia in animal models. *Pharmaceutical Biology*, **2019**, 57, 717-728	3.8	5
32	A novel mouse model for septic arthritis induced by Pseudomonas aeruginosa. *Scientific Reports*, **2019**, 9, 16868	4.9	4
31	A Mast-Cell-Specific Receptor Mediates Neurogenic Inflammation and Pain. *Neuron*, **2019**, 101, 412-420.e3	13.9	127
30	Synthesis, H-labelling and in vitro evaluation of a substituted dipiperidine alcohol as a potential ligand for chemokine receptor 2. *Journal of Labelled Compounds and Radiopharmaceuticals*, **2019**, 62, 265-279	1.9	2
29	Monocyte chemoattractant protein-1 (MCP-1/CCL2) in diabetic retinopathy: latest evidence and clinical considerations. *Journal of Cell Communication and Signaling*, **2019**, 13, 451-462	5.2	29
28	Crystal Structure of CC Chemokine Receptor 2A in Complex with an Orthosteric Antagonist Provides Insights for the Design of Selective Antagonists. *Structure*, **2019**, 27, 427-438.e5	5.2	20
27	The chemokine system and its role in obesity. *Journal of Cellular Physiology*, **2019**, 234, 3336-3346	7	21
26	The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Research*, **2020**, 182, 104902	10.8	14
25	Tailor-Made Amino Acids and Fluorinated Motifs as Prominent Traits in Modern Pharmaceuticals. *Chemistry - A European Journal*, **2020**, 26, 11349-11390	4.8	50

24	Preconditioning of Adipose-Derived Mesenchymal Stem-Like Cells with Eugenol Potentiates Their Migration and Proliferation In Vitro and Therapeutic Abilities in Rat Hepatic Fibrosis. *Molecules*, **2020**, 25,	4.8	12
23	Development of a Robust Protocol for the Synthesis of 6-Hydroxybenzofuran-3-carboxylic Acid. *Organic Process Research and Development*, **2020**, 24, 861-866	3.9	1
22	Evaluation of goserelin effectiveness based on assessment of inflammatory cytokines and symptoms in uterine leiomyoma. *International Journal of Clinical Pharmacy*, **2020**, 42, 931-937	2.3	3
21	Effect of a monocyte chemoattractant protein-1 synthesis inhibitor on fibroblasts from patients with carpal tunnel syndrome. *Journal of Orthopaedic Science*, **2021**, 26, 295-299	1.6	0
20	Inhibition of macrophage migration in zebrafish larvae demonstrates in vivo efficacy of human CCR2 inhibitors. *Developmental and Comparative Immunology*, **2021**, 116, 103932	3.2	1
19	The molecular structure and role of CCL2 (MCP-1) and C-C chemokine receptor CCR2 in skeletal biology and diseases. *Journal of Cellular Physiology*, **2021**, 236, 7211-7222	7	9
18	Differential Effects of Angiotensin-II Compared to Phenylephrine on Arterial Stiffness and Hemodynamics: A Placebo-Controlled Study in Healthy Humans. *Cells*, **2021**, 10,	7.9	1
17	Efficacy and action mechanisms of a Chinese herbal formula on experimental models of atopic dermatitis. *Journal of Ethnopharmacology*, **2021**, 274, 114021	5	0
16	Anti-inflammatory Effects of Probiotics and Their Metabolites: Possible Role for Epigenetic Effects. **2014**, 127-150		1
15	Epithelial-macrophage interactions determine pulmonary fibrosis susceptibility in Hermansky-Pudlak syndrome. *JCI Insight*, **2016**, 1, e88947	9.9	47
14	Association of cord blood chemokines and other biomarkers with neonatal complications following intrauterine inflammation. *PLoS ONE*, **2017**, 12, e0175082	3.7	20
13	Selective agonist of TRPML2 reveals direct role in chemokine release from innate immune cells. *ELife*, **2018**, 7,	8.9	46
12	Chemokine receptor antagonist development. *Methods in Molecular Biology*, **2013**, 1013, 67-92	1.4	
11	Vascular Inflammation in Ischemic Stroke: Adhesion Receptors Controlling Leukocyte-Endothelial Interactions. **2014**, 27-51		
10	Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?. *Frontiers in Immunology*, **2021**, 12, 771210	8.4	12
9	Biomarkers of endothelial dysfunction in Black South African HIV-positive subjects are associated with both high viral load and low CD4 counts.. *AIDS Research and Human Retroviruses*, **2021**,	1.6	0
8	Synthesis of Deuterium-Labeled CCR2 Antagonist JNJ-26131300, [4-(1H-Indol-3-yl)-piperidin-1-yl]-{1-[3-(3,4,5-trifluoro-phenyl)-acryloyl]-piperidin-4-yl}-acetic acid.. *Journal of Labelled Compounds and Radiopharmaceuticals*, **2022**,	1.9	
7	Effects of Dexmedetomidine on Immune Cells: A Narrative Review.. *Frontiers in Pharmacology*, **2022** , 13, 829951	5.6	0

6	T cell morphodynamics reveal periodic shape oscillations in three-dimensional migration.. *Journal of the Royal Society Interface*, **2022**, 19, 20220081	4.1	1
5	Roles of CCL2 and CCL3 in intraocular inflammation during Bacillus endophthalmitis. **2022**, 224, 109213		0
4	Role of CCL2/CCR2 axis in the pathogenesis of COVID-19 and possible Treatments: All options on the Table. **2022**, 113, 109325		1
3	Immunostimulatory activity of hydrolyzed and fermented Platycodon grandiflorum extract occurs via the MAPK and NF-**B** signaling pathway in RAW 264.7 cells. **2022**, 16, 685		1
2	Pathophysiology of Diabetic Macular Edema. **2022**, 7-25		0
1	Co-Targeting IL-6 and EGFR signaling for the treatment of schwannomatosis and associated pain.		0